<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C745868C-1A14-451E-90DA-D92FDE99B4CA"><gtr:id>C745868C-1A14-451E-90DA-D92FDE99B4CA</gtr:id><gtr:name>University Cheikh Anta Diop de Dakar</gtr:name><gtr:address><gtr:line1>BP 5005</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F040A04-142E-43C9-BBAA-33D2D726CC93"><gtr:id>8F040A04-142E-43C9-BBAA-33D2D726CC93</gtr:id><gtr:name>The Statens Serum Institute (SSI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/97889367-1389-4ADD-96A8-E8D3579259E8"><gtr:id>97889367-1389-4ADD-96A8-E8D3579259E8</gtr:id><gtr:name>University of Jos</gtr:name><gtr:address><gtr:line1>PMB 2084</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/58930F3F-9B16-4DC2-833F-C72033E77A1E"><gtr:id>58930F3F-9B16-4DC2-833F-C72033E77A1E</gtr:id><gtr:name>Boston Children's Hospital</gtr:name><gtr:address><gtr:line1>Boston Childrens Hospital</gtr:line1><gtr:line2>Karp Building</gtr:line2><gtr:line3>9th floor, Rm 09210 1 Blackfan Circle</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C745868C-1A14-451E-90DA-D92FDE99B4CA"><gtr:id>C745868C-1A14-451E-90DA-D92FDE99B4CA</gtr:id><gtr:name>University Cheikh Anta Diop de Dakar</gtr:name><gtr:address><gtr:line1>BP 5005</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F040A04-142E-43C9-BBAA-33D2D726CC93"><gtr:id>8F040A04-142E-43C9-BBAA-33D2D726CC93</gtr:id><gtr:name>The Statens Serum Institute (SSI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C711771-B8F6-4CDF-9AC3-9FAB317463D9"><gtr:id>2C711771-B8F6-4CDF-9AC3-9FAB317463D9</gtr:id><gtr:name>University of Cape Town</gtr:name><gtr:address><gtr:line1>Private Bag</gtr:line1><gtr:line2>Rondebosch</gtr:line2><gtr:postCode>7700</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8D6A87B-48C3-49DC-8D55-AA7203607683"><gtr:id>A8D6A87B-48C3-49DC-8D55-AA7203607683</gtr:id><gtr:name>University of British Columbia (UBC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/97889367-1389-4ADD-96A8-E8D3579259E8"><gtr:id>97889367-1389-4ADD-96A8-E8D3579259E8</gtr:id><gtr:name>University of Jos</gtr:name><gtr:address><gtr:line1>PMB 2084</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/58930F3F-9B16-4DC2-833F-C72033E77A1E"><gtr:id>58930F3F-9B16-4DC2-833F-C72033E77A1E</gtr:id><gtr:name>Boston Children's Hospital</gtr:name><gtr:address><gtr:line1>Boston Childrens Hospital</gtr:line1><gtr:line2>Karp Building</gtr:line2><gtr:line3>9th floor, Rm 09210 1 Blackfan Circle</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E89DF462-9EA4-4042-B006-DC19F73B5B9E"><gtr:id>E89DF462-9EA4-4042-B006-DC19F73B5B9E</gtr:id><gtr:firstName>Beate</gtr:firstName><gtr:surname>Kampmann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E6573CA8-B03B-4057-85A6-D305F41C2F6F"><gtr:id>E6573CA8-B03B-4057-85A6-D305F41C2F6F</gtr:id><gtr:firstName>Azra</gtr:firstName><gtr:otherNames>Catherine</gtr:otherNames><gtr:surname>Ghani</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ABFA5DFF-3E81-41B3-B818-7228EE75DA9D"><gtr:id>ABFA5DFF-3E81-41B3-B818-7228EE75DA9D</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>Campbell</gtr:otherNames><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C166EF2D-FBDF-4D1F-A789-7379B587FF9C"><gtr:id>C166EF2D-FBDF-4D1F-A789-7379B587FF9C</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Antonio</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/224E3DE5-2D34-44B1-85D6-F106532CBF36"><gtr:id>224E3DE5-2D34-44B1-85D6-F106532CBF36</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Ota</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_EX_MR%2FK011944%2F1"><gtr:id>3638CE83-470D-4AC6-A62C-5BF3DC6B515F</gtr:id><gtr:title>Childhood tuberculosis: Integrating tools for improved diagnosis and vaccines</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_EX_MR/K011944/1</gtr:grantReference><gtr:abstractText>TB often occurs in households, which is where children are particularly likely to catch it from an infected adult. But not everyone gets it when exposed to a coughing &amp;quot;index case&amp;quot;, which is the coughing person with active TB. It is likely that many factors like the organism in question, the conditions of the household and also the responses of the immune system of the individual child play a role. We have a large gap in our understanding of the transmission, susceptibility and what kind of immunity is needed to fend off the TB bacteria. This is why we have so far failed to make a better vaccine than the current vaccine, BCG, which is not fully protective. If we understand the mechanisms that underlie susceptibility and protection, this would be very useful for any trials of new vaccines, but also for the diagnosis, as we could look for specific markers associated with TB disease and protection. Such markers could also be used in vaccine or treatment trials, instead of purely relying on the bacteriologically confirmed cases, which is the current approach. In our project, we will develop and test novel approaches by using new methods in the microbiology and immunology laboratory and have brought together a strong team of internal and external experts to be able to use all the state-of-the art available methodology. We now have a candidate biosignature which has been patented and will be evaluated in additional cohorts.</gtr:abstractText><gtr:technicalSummary>Tuberculosis causes significant morbidity and mortality in children worldwide. Bacteriological confirmation of TB in children is rare and lack of suitable alternative diagnostics is a major bottleneck to progress in identifying patients in need of treatment and in clinical trials of new vaccines and therapies. The MRC Unit, The Gambia can make a significant contribution in this field, since it has a track record in TB research, established data collection tools and state-of-the art laboratory facilities. Suitable cohorts of children with TB disease, infected and controls can be predicted. Our team of local and international investigators is developing and evaluating existing and new tools based on both host immune response and microbiology. We also work with new external collaborators, who are highly experienced in statistical analysis. We are testing samples from TB-affected children (exposed, infected or diseased) identified in household cohorts by using a combined approach of host and pathogen signatures and cellular and molecular methods, such as GeneXpert and biosignatures (ERJ 2015, IUATLD 2016). We characterise host responses associated with protection against infection in TB-exposed children who remain uninfected and who can serve as a model for protective immunity (MRC PhD studentship). We have expaned our existing epidemiological database to include the epidemiological and microbiological context of household transmission and its impact on host responses. We are developing a novel statistical approach to design prediction algorithms for the diagnosis of childhood TB. Translation to Policy: Our research activities have doubled the notification figures for childhood TB in The Gambia. We have developed and patented a novel diagnostic biosignature. Integration of measurable host responses into diagnostic algorithms is informing not only the diagnosis of the individual patient but also facilitate clinical trials of new vaccines and drugs. Understanding of protective immune mechanisms will guide vaccine design. Epidemiological datasets that link TB exposure, infection and disease can serve as a model for public health and TB control. We are working with the NLPT to transfer the household contact tracing into the national program.</gtr:technicalSummary><gtr:potentialImpactText>Tuberculosis remains a global emergency and affects and continues to kill adults and children in large numbers worldwide.
Our project proposal has been developed to address a critical bottleneck for patient management and clinical trials of new vaccines and drugs alike: a) the problem of accurate diagnostics for tuberculosis (TB) in children and b) the absence of markers of protection which can be used as endpoints for TB vaccine trials. This bottleneck is widely acknowledged by the scientific community and international TB program officers, and remains at the center of international research efforts. This was highlighted in the special supplement to the Journal of Infectious Disease, published on World TB Day 2012 and dedicated to basic research but also implementation obstacles for TB globally. 
Without a better diagnostic approach, which doesn't exclusively rely on bacteriological confirmation, children are not likely to be included in any studies of improved treatment for TB, and any ongoing vaccine trials will continue to require large and expensive cohorts of patients to be followed prospectively over a long period of time. This is prohibitively expensive and will preclude the evaluation of promising vaccine candidates as there simply are not enough field sites available that can provide both sizeable paediatric cohorts and have the laboratory and clinical capacity to follow them up in clinical trials.
Our research program will impact on areas of discovery, development and delivery within childhood tuberculosis. All of these are required and have merit in driving forward the agenda to improve the diagnosis and treatment of individual cases of TB in children and ultimately also facilitate clinical trials for new treatments and vaccines. 
Discovery: the identification of new biomarkers and host/pathogen signatures will drive the development of point-of care tests for TB by identifying new leads in either metabolomics, cytokine or gene signatures, which are amenable to further development with the help of industry partners and not-for profit organisations such as FIND/PATH. To understand mechanisms of protection against infection opens up a key avenue for vaccine design and evaluation, as ultimately, only a TB vaccine that prevents infection and disease will have the desired public health impact for TB control.
Development: we expect that the evaluation of recently identified biosignatures from adult populations will confirm preliminary results also in children and will then stimulate the development of more user-friendly versions of assays, including translation into nanotechnological and lateral flow-based assays, again partnering with industry in the future.
Delivery: The assessment of impact of epidemiological components for household transmission and the analysis of additional laboratory assays built into the diagnostic algorithms will lend support for the planning of interventions and mobilisation of resources for policy makers in TB and the national TB programs in a variety of settings, depending on resources available. The aim of this particular objective is to develop further policy links and share the algorithms and toolbox concept with our partners in NLTP in resource-poor and -rich settings. We anticipate that these algorithms could be tailored according to available resources and require to be evaluated in a variety of populations (+/- HIV). We will then liaise with experts in cost-effectiveness analysis (i.e. Imperial College Business school, HPA, WHO) to quantify the potential need for resources, depending on the algorithm chosen. This will allow the TB program decision makers to develop more appropriate predictions of impact depending on the settings that wish to adapt them.Through close links between our research and the National Leprosy and TB program (NLTP), the experience in The Gambia will inform international TB control efforts via communication channels such as the StopTB partnership and WHO.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cape Town</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:department>Institute of Infectious Disease and Molecular Medicine (IIDMM)</gtr:department><gtr:description>IIDMM UCT</gtr:description><gtr:id>0F2B5E8F-AF1E-469D-BFFC-98F8FD27277F</gtr:id><gtr:impact>joint publications
joint grant applications</gtr:impact><gtr:outcomeId>BGcCH68zKDS-1</gtr:outcomeId><gtr:partnerContribution>access to lab and field</gtr:partnerContribution><gtr:piContribution>joint supervision of PhD students
academic links in the field of TB
grant money to UCT</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boston Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Levy Laboratory</gtr:department><gtr:description>Levy Lab</gtr:description><gtr:id>2EDDBC5F-2307-40C1-80A8-20EEB4B175A8</gtr:id><gtr:impact>several publications and a grant submission to the nIH</gtr:impact><gtr:outcomeId>56cf4bb1cea7e0.22270866-1</gtr:outcomeId><gtr:partnerContribution>bioinformatics support</gtr:partnerContribution><gtr:piContribution>set up of systems vaccinology research for studies of EPI vaccines</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Universit? Cheikh Anta Diop de Dakar, Dakar</gtr:collaboratingOrganisation><gtr:country>Senegal, Republic of</gtr:country><gtr:description>UCAD</gtr:description><gtr:id>E793D57B-2D85-4D18-9577-1AD79A21890B</gtr:id><gtr:impact>scientific workshops</gtr:impact><gtr:outcomeId>58b0aa84d13e24.57477745-1</gtr:outcomeId><gtr:partnerContribution>exchange of ideas and potential for join grant applications</gtr:partnerContribution><gtr:piContribution>Professor Mboup and Professor Gaye are partners in our West African Global Health Research initiative and a number of members of their respective departments are now involved in our research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Statens Serum Institute (SSI)</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Staten Serum Institute Denmark</gtr:description><gtr:id>3A26996A-0485-4CFC-B918-66F6FF61FD1E</gtr:id><gtr:impact>joint publications</gtr:impact><gtr:outcomeId>A6VLtZf6QTG-1</gtr:outcomeId><gtr:partnerContribution>availability of reagents to our research study</gtr:partnerContribution><gtr:piContribution>application of reagents in research studies</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Vaccine Group</gtr:department><gtr:description>Oxford Vaccine Group</gtr:description><gtr:id>A82C3BC6-47F7-4EEA-B4E2-811E4022D5C5</gtr:id><gtr:impact>new collaboration</gtr:impact><gtr:outcomeId>54565254e40397.00524183-1</gtr:outcomeId><gtr:partnerContribution>joint supervision of PhD student</gtr:partnerContribution><gtr:piContribution>mutual engagement in Vaccinology research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of British Columbia</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Department of Pediatrics</gtr:department><gtr:description>British Columbia University</gtr:description><gtr:id>ACFE600D-499E-4708-B41D-4211A7D500A3</gtr:id><gtr:impact>publication, presentation at international meeting, visibility</gtr:impact><gtr:outcomeId>56cf4c26485a85.68543889-1</gtr:outcomeId><gtr:partnerContribution>access to protocols</gtr:partnerContribution><gtr:piContribution>provided support for field sample collections and vaccinations, plus laboratory facilities</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>University of Munich</gtr:description><gtr:id>284BD3C8-F056-4C8F-892C-12A6C8D97565</gtr:id><gtr:impact>the study is just starting, the website is being developed</gtr:impact><gtr:outcomeId>58b0abf572d295.14663104-1</gtr:outcomeId><gtr:partnerContribution>LMU is the grant holder and chose my TB program at MRC and the TBCC as a partner site in this 5-counry multicentre study.</gtr:partnerContribution><gtr:piContribution>Collaborative grant award from the German ministry to conduct research into lung sequelae of TB</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Infectious Diseases</gtr:department><gtr:description>TB-CDRC</gtr:description><gtr:id>377F33FB-DB8D-4BB6-993F-488C256B10B6</gtr:id><gtr:impact>consensus statement on TB diagnostics classification for children- see publications list</gtr:impact><gtr:outcomeId>Y6ewoFwQaGR-1</gtr:outcomeId><gtr:partnerContribution>regular input into paediatric study design and review of evolving concept sheets</gtr:partnerContribution><gtr:piContribution>I act a s the director of paediatric studies in this consortium which has a large grant from the NIH to conduct research into TB diagnostics</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Jos</gtr:collaboratingOrganisation><gtr:country>Nigeria, Federal Republic of</gtr:country><gtr:department>Department of Paediatrics</gtr:department><gtr:description>University of Jos, Nigeria</gtr:description><gtr:id>5DD06939-4B7E-4114-B1E5-87EE5DF52BDF</gtr:id><gtr:impact>Foundation Award MRC</gtr:impact><gtr:outcomeId>58b0ab40990756.55306493-1</gtr:outcomeId><gtr:partnerContribution>set up of validators cohorts for childhood TB research</gtr:partnerContribution><gtr:piContribution>A paediatrician form Jos is developing a research project under my supervision and received funding via Imperial College in 2016. He is now also a collaborator on the Foundation GCRF award</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World TB Day community activities</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5513D152-AEFD-47BF-826D-144A5D5CC4D7</gtr:id><gtr:impact>For the World TB day on March 24th we coordinated joint activities with the NLTP of The Gambia in a coastal community. Schoolchildren and lay audience as well as healthcare workers and patents participated.</gtr:impact><gtr:outcomeId>58b0ba39d74928.09558402</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.mrc.gm/mrc-unit-tb-research-world-tb-day-celebration/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Inaugural lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4EC9E23-8290-4C3A-8383-41EC5CE2E4B4</gtr:id><gtr:impact>Travel with T cells, now on YouTube

inerest in academic medicine by GCSE-level students, several University students requesting mentorship</gtr:impact><gtr:outcomeId>Xtsp4briKxC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lancet personal profile</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A246C30B-5993-47F7-BB9C-D60576F8D371</gtr:id><gtr:impact>Personal Profile in The Lancet entitled&amp;quot; Professor Beate Kampmann: Advocate for Childhood Tuberculosis&amp;quot;

invitations to present work at various international meetings</gtr:impact><gtr:outcomeId>aEp1AsseCoY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship for Dr Basu-Roy</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D861ED68-9B80-4E83-AEDC-527CD04BA82B</gtr:id><gtr:outcomeId>ZvjjCTdn8Fo</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>580000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GCRF</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D51B1EC1-30C3-49B2-85F9-2681C7EB3862</gtr:id><gtr:outcomeId>58b0b666ba36e4.41387063</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC studentship Dr Togun</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6DD8839E-F723-4275-8E97-2E7D5FC637A5</gtr:id><gtr:outcomeId>bzNAFdSMFX2</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Program grant</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>MRC Harwell</gtr:fundingOrg><gtr:id>2EF3799E-6426-4D0C-8FFB-94DCF67228E9</gtr:id><gtr:outcomeId>545bd3faa1efc8.60989224</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship Dr Saikou Bah</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>198942D8-F569-4F26-AAAD-67B3D0D1494D</gtr:id><gtr:outcomeId>gB2pEF6XNe1</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3066638</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Networks of Excellence EDCTP</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>020F463C-193B-49E0-B740-F01A3305B42C</gtr:id><gtr:outcomeId>58b0b894487804.51769408</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>PhD studentship Dr Egere</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Ludwig Maximilian University of Munich (LMU Munich)</gtr:fundingOrg><gtr:id>17D25D6E-C30B-4FDA-818C-A7E76499099D</gtr:id><gtr:outcomeId>igTps7dvsCr</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>German Government- BMBF- International collaborations</gtr:description><gtr:end>2021-06-02</gtr:end><gtr:fundingOrg>German Federal Ministry of Education and Research</gtr:fundingOrg><gtr:id>70EE7F99-0235-4250-B579-F29A94EB9249</gtr:id><gtr:outcomeId>56d1a6045e7543.02049859</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>this patent application is a direct result of the work conducted on my MRC program grant. it protects a diagnostic biosignature for childhood TB which can now be taken forward for further evaluation and potentially developed into a POC test.</gtr:description><gtr:grantRef>MC_EX_MR/K011944/1</gtr:grantRef><gtr:id>00E7662C-07FC-4BC8-8C75-82993F6CFAA0</gtr:id><gtr:impact>only just filed</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56cf54b0e0f4e6.44122342</gtr:outcomeId><gtr:patentId>P10280GB</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Patent for TB biomarker signature</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Press panel RCPCH</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EE27841C-EFE4-4780-A9ED-D76657876863</gtr:id><gtr:outcomeId>tCBomKswfMn</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ECDC advocacy workshop</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9785527D-7166-4C9A-90E5-EA5110616E2D</gtr:id><gtr:impact>Raising the profile of paediatric tuberculosis in international organisations such as ECDC and WHO has led to the inclusion of recommendations specifically for children in the guidelines.</gtr:impact><gtr:outcomeId>D919epUH1Ko</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>guidelines for use of IGRA in children</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8FC2DF30-C097-41A8-A62D-AA6E10FB993E</gtr:id><gtr:impact>our research has clearly identified the correct use of IGRA for the the diagnosis of TB in children. We were commissioned to publish our guidelines in a UK Education?actice Journal, which has an international audience</gtr:impact><gtr:outcomeId>ZdQfLvmap8r</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIH case-definition workshop</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9A539CB0-081E-466F-8123-EA37934A3161</gtr:id><gtr:outcomeId>jqBhv16EVSX</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Assistance to the National TB program</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E64F0A8D-E5DE-4716-9C18-2D3864613AED</gtr:id><gtr:impact>The training program in childhood tuberculosis which was established through my program grant has led to a doubling of the notification of cases of childhood TB in the country.
It has also led to the request for our involvement to assist the National Leprosy and TB Program of The Gambia in their preparation for the application for funding to the Global Fund. This request for funding was granted and now also includes more provision of services for children.</gtr:impact><gtr:outcomeId>56d1a847eca595.62205176</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>work cited in international guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>5124F424-CDE8-45F3-9E81-03B52866523F</gtr:id><gtr:impact>rational use of resources</gtr:impact><gtr:outcomeId>sLjZBuUaHBp</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Update of classification for childhood TB</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>NIH Classification of childhood TB</gtr:guidelineTitle><gtr:id>BF9E8483-C6EF-443F-9051-9BB0F52C5C4B</gtr:id><gtr:impact>The definitions for childhood TB have facilitate the notifications of the condition to the WHO and the rise of age-disaggregated data in the reports to the Who has been phenomenal. The reporting of childhood TB in The Gambia rose by 60% since I initiated the childhood TB research program.</gtr:impact><gtr:outcomeId>56cf5188b2b793.18520296</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>New classification of childhood tuberculosis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C62E1D5C-8FAD-4E98-9834-7EDCBA1D7518</gtr:id><gtr:impact>the NIH-commissioned workshop of which I was an invited member drafted a new case classification for research in childhood tuberculosis. This classification is now standard to attract funding for diagnostic-related research in this area.</gtr:impact><gtr:outcomeId>U75ZeRknkKD</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Book chapter in new book on childhood TB</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A3ACA297-CB3B-405D-A50A-8052A6CC7A61</gtr:id><gtr:impact>I am the author of the chapter on immunology in the new book on childhood and adolescent TB recently published by Starke and Donaldson- this textbook is virtually the only available textbook and to be asked to author a chapter pays tribute to my international standing in the field.</gtr:impact><gtr:outcomeId>56cf52ae88d027.70290309</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO advisory board</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>CBD86483-7F19-4CE1-92F6-2A8665A4A8F1</gtr:id><gtr:impact>improvements in delivery of clinical services to children exposed to TB by advocating contact tracing for vulnerable groups in the WHO guideline document to which I contributed</gtr:impact><gtr:outcomeId>c53US1AyxbG</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This database links index cases and contacts affected by tuberculosis</gtr:description><gtr:id>5EF830BB-911F-43A5-B11C-ED2FE750924D</gtr:id><gtr:impact>The set up of the database in The Gambia is also a useful tool for the TB research at Imperial College and has been shared in an anonymised way with all ethical approvals</gtr:impact><gtr:outcomeId>545659317c3ac1.57623900</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>database for TB contacts in households</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>I generated a new generation of reporter-gene tagged mycobacteria in my lab which facilitates studies of host/pathogen interaction</gtr:description><gtr:id>6A6C678B-906B-4E3A-B833-FE7757AD400D</gtr:id><gtr:impact>new assay for high throughput of drug screening set up</gtr:impact><gtr:outcomeId>56cf53dbd88277.55097143</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>reporter gene mycobacteria</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>the contact tracing model was developed by my TB research group to facilitate the linking of index cases to childhood contacts. it has been developed in collaboration with public health england and an adapted version also in use at the MRC Unit in The Gambia.</gtr:description><gtr:id>5D7665D3-9F03-4C16-8821-02539727E2B2</gtr:id><gtr:impact>contact tracing and chemoprophylaxis for children is now part of the activities of the National TB program in the Gambia</gtr:impact><gtr:outcomeId>pm8jmT4HUPV</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>design of a public health contact tracing model for TB control in the community</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>22D5F82C-CDED-4E86-88B1-2EF1A8426341</gtr:id><gtr:title>Embracing the challenges of HIV-TB co-infection in children.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a9050d5956f85b865bf30ed8ee0537a"><gtr:id>1a9050d5956f85b865bf30ed8ee0537a</gtr:id><gtr:otherNames>van Leth F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>545bcfec183a29.02677474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C5B441C-2A7A-46F0-91A6-ED9424A91C45</gtr:id><gtr:title>Rapid diagnosis of tuberculosis using ex vivo host biomarkers in sputum.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>545bcfec63b365.13574982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C0F5CC3-41BB-45E6-B70D-ED1FC3A78005</gtr:id><gtr:title>Non-tuberculous mycobacteria in children: muddying the waters of tuberculosis diagnosis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ec537c5d18a4442d5c2085be8cdbeb0"><gtr:id>2ec537c5d18a4442d5c2085be8cdbeb0</gtr:id><gtr:otherNames>L?pez-Varela E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>56cf4a9c69a6a4.37351816</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B001953-7CFC-402D-9DF8-C27F72FC2D9E</gtr:id><gtr:title>Anti-group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2918f0e3820429f15952099f7448aa4"><gtr:id>f2918f0e3820429f15952099f7448aa4</gtr:id><gtr:otherNames>Le Doare K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56cf4a9d4e5694.79030154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC1C6C55-6B3A-4552-8E75-7311E9C9E8CE</gtr:id><gtr:title>No added value of interferon-? release to a prediction model for childhood tuberculosis.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20cdfef2eadb068c553328286c9523b5"><gtr:id>20cdfef2eadb068c553328286c9523b5</gtr:id><gtr:otherNames>Togun TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>56cf4a9e349f50.46296639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4FA87A8-0E31-4A36-9E10-FFB4E4D788E1</gtr:id><gtr:title>Biological challenges to effective vaccines in the developing world.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad477705d4c8966434296d200f476ba2"><gtr:id>ad477705d4c8966434296d200f476ba2</gtr:id><gtr:otherNames>Grassly NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>56cf4a9bb3f289.90944936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7230084E-88FF-471E-9910-34AC61AE2CE6</gtr:id><gtr:title>Differential transcriptomic and metabolic profiles of M. africanum- and M. tuberculosis-infected patients after, but not before, drug treatment.</gtr:title><gtr:parentPublicationTitle>Genes and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1466-4879</gtr:issn><gtr:outcomeId>56cf4a9a549ca0.87837602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB23192A-E64F-490C-897C-41B606FC1C2A</gtr:id><gtr:title>Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/914a5d9d73e66a78a254c31b21274506"><gtr:id>914a5d9d73e66a78a254c31b21274506</gtr:id><gtr:otherNames>Graham SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cf4a9a225c51.62551612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45FBA336-32C0-4868-9715-6F5B9A57E177</gtr:id><gtr:title>Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>545bd09798cf83.82588365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67C9D30B-4F73-43E4-994D-9F1589DAF36C</gtr:id><gtr:title>How to use: interferon ? release assays for tuberculosis.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood. Education and practice edition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91890f7a1b667277c672c547c0673a1d"><gtr:id>91890f7a1b667277c672c547c0673a1d</gtr:id><gtr:otherNames>Pollock L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1743-0585</gtr:issn><gtr:outcomeId>pm_13512_22_23580543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79C93248-BCA3-48D6-BFD5-87466836F758</gtr:id><gtr:title>The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Gu&amp;eacute;rin vaccination.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bdffc049adbcb99401d65c52e5ff669"><gtr:id>3bdffc049adbcb99401d65c52e5ff669</gtr:id><gtr:otherNames>Jones CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56cf4a9dc7ca24.38443287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24528AE9-7A6B-462F-BBF9-661DBDF7D487</gtr:id><gtr:title>Toxicity and tolerability of fluoroquinolone-based preventive therapy for childhood contacts of multidrug-resistant tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff0ce7c349f66f838975792025ead9f1"><gtr:id>ff0ce7c349f66f838975792025ead9f1</gtr:id><gtr:otherNames>Seddon JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>545bcf45cac997.42576787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CDD12FE-FDD7-48B0-826B-E2888EDC0586</gtr:id><gtr:title>Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8630d38a88c3f539cee58b8275068ee2"><gtr:id>8630d38a88c3f539cee58b8275068ee2</gtr:id><gtr:otherNames>Idoko OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5a9eed079952c5.38293798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D89CB01-0B86-4BC1-9ED9-9A573BA71386</gtr:id><gtr:title>Management of child MDR-TB contacts across countries in the WHO European Region: a survey of current practice.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c159370750a8c30de0c07f31162d2e5"><gtr:id>4c159370750a8c30de0c07f31162d2e5</gtr:id><gtr:otherNames>Turkova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>5a9eed088a5a64.66359210</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9314D19-7045-41CB-AF6A-B5A5F802410E</gtr:id><gtr:title>Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff0ce7c349f66f838975792025ead9f1"><gtr:id>ff0ce7c349f66f838975792025ead9f1</gtr:id><gtr:otherNames>Seddon JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cf4a9acc27f9.33883015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E793AF5-697B-4BB2-A64C-176EB89E248A</gtr:id><gtr:title>Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4343631aee7697faab563179dbe32c1"><gtr:id>a4343631aee7697faab563179dbe32c1</gtr:id><gtr:otherNames>Elliott TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56cf4a4491cb22.54205386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86983512-7E28-4943-B706-3AA2A4EC98DE</gtr:id><gtr:title>Effect of Antiretroviral Therapy on HIV-mediated Impairment of the Neutrophil Antimycobacterial Response.</gtr:title><gtr:parentPublicationTitle>Annals of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fffeea0403dfb5c4fb207ad1992bd697"><gtr:id>fffeea0403dfb5c4fb207ad1992bd697</gtr:id><gtr:otherNames>Lowe DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2325-6621</gtr:issn><gtr:outcomeId>56cf4a999e82e6.17197797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAAF9356-C42F-4624-AD7E-5C0B7DE048CF</gtr:id><gtr:title>Why the Convention on the Rights of the Child must become a guiding framework for the realization of the rights of children affected by tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC international health and human rights</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb1713935960ba4e6ada861507a76d09"><gtr:id>bb1713935960ba4e6ada861507a76d09</gtr:id><gtr:otherNames>Basu Roy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-698X</gtr:issn><gtr:outcomeId>58b0a99a3d6072.47716200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>394519E0-F812-48FA-9B58-8BA3FAB32992</gtr:id><gtr:title>Monocyte unresponsiveness and impaired IL1?, TNFa and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4d57e7ccac0cf1e7cbdb915c51fa748"><gtr:id>e4d57e7ccac0cf1e7cbdb915c51fa748</gtr:id><gtr:otherNames>Waitt CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>56cf4a9e8e32d1.89852719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14120A2C-5DAE-4B86-8D88-14939F985161</gtr:id><gtr:title>Paediatric emergency care in resource-limited settings.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91890f7a1b667277c672c547c0673a1d"><gtr:id>91890f7a1b667277c672c547c0673a1d</gtr:id><gtr:otherNames>Pollock L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_13512_22_23601944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB96CE9E-C371-4D71-A141-1806C334F9F2</gtr:id><gtr:title>Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8630d38a88c3f539cee58b8275068ee2"><gtr:id>8630d38a88c3f539cee58b8275068ee2</gtr:id><gtr:otherNames>Idoko OT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cf4a45ae80b2.33967162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6400FAC-7772-496A-B2F1-016A8E1E77BC</gtr:id><gtr:title>Childhood tuberculosis is associated with decreased abundance of T cell gene transcripts and impaired T cell function.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a9136959e410b91bf6d047213a4f31f"><gtr:id>4a9136959e410b91bf6d047213a4f31f</gtr:id><gtr:otherNames>Hemingway C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a9eed04df9b56.79544154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66170917-7A43-4162-89D9-886800FD427D</gtr:id><gtr:title>The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8fa3e311c4f6e1e8f3a5e0ddf1c1d88"><gtr:id>a8fa3e311c4f6e1e8f3a5e0ddf1c1d88</gtr:id><gtr:otherNames>Dodd PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58b0a999cc31a5.95382480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD222498-56EC-4635-8A72-E4DC6D1E6A68</gtr:id><gtr:title>Evaluating UK National Guidance for Screening of Children for TB: A Prospective Multi-centre Study.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda45a6a26a4e43dac5e1b063bbf789a"><gtr:id>cda45a6a26a4e43dac5e1b063bbf789a</gtr:id><gtr:otherNames>Kampmann B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5a9eecc4b94040.42135911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AA33B7F-C2A1-45C0-86D4-694F1508C8C5</gtr:id><gtr:title>Increased disease due to Haemophilus influenzae type b: population-based surveillance in eastern Gambia, 2008-2013.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ed8fbc4f7229b333b42393e35226ed"><gtr:id>91ed8fbc4f7229b333b42393e35226ed</gtr:id><gtr:otherNames>Mackenzie GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>56cf4a9ca76026.07722478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9122FDF-D219-4D41-8F85-6B3FEB089EF9</gtr:id><gtr:title>What determines uptake of pertussis vaccine in pregnancy? A cross sectional survey in an ethnically diverse population of pregnant women in London.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c60cf4464ca6d927f8455ce0d2d5a240"><gtr:id>c60cf4464ca6d927f8455ce0d2d5a240</gtr:id><gtr:otherNames>Donaldson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56cf4a45023153.68878350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F708378E-0D59-4959-BC03-3B56AA002CE0</gtr:id><gtr:title>Ebola: a holistic approach is required to achieve effective management and control.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56cf4a9cd6f400.37358736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0078F42D-F3DB-468B-91BA-4EEDBCB4A1C9</gtr:id><gtr:title>Current understanding of the immune response to tuberculosis in children.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb1713935960ba4e6ada861507a76d09"><gtr:id>bb1713935960ba4e6ada861507a76d09</gtr:id><gtr:otherNames>Basu Roy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>pm_13512_22_22491144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CE48953-5A81-47B1-8169-9EFF78A248A3</gtr:id><gtr:title>Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41a1121db9f971503c2bd7f8fa4d4247"><gtr:id>41a1121db9f971503c2bd7f8fa4d4247</gtr:id><gtr:otherNames>Scott S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>56cf4a9d203547.98481274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F234DECF-EBA0-45C6-814A-875A73120484</gtr:id><gtr:title>Immunogenic Mycobacterium africanum strains associated with ongoing transmission in The Gambia.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2765a26bdd37caa8fbd71943ba6d74a8"><gtr:id>2765a26bdd37caa8fbd71943ba6d74a8</gtr:id><gtr:otherNames>Gehre F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>pm_13512_22_24050158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2049FE3-B247-46D4-9A21-23170279DAC1</gtr:id><gtr:title>A multimedia consent tool for research participants in the Gambia: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd0b08c7569d3fbb892d3070c540098"><gtr:id>5bd0b08c7569d3fbb892d3070c540098</gtr:id><gtr:otherNames>Afolabi MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>56cf4a9b572c64.59953225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>260C092B-EE6F-4E91-A667-9949F5FCD44B</gtr:id><gtr:title>Contribution of Xpert&amp;reg; MTB/RIF to the diagnosis of pulmonary tuberculosis among TB-exposed children in The Gambia.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20cdfef2eadb068c553328286c9523b5"><gtr:id>20cdfef2eadb068c553328286c9523b5</gtr:id><gtr:otherNames>Togun TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>56cf4a9b217e21.66685232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67DD6291-250D-4E1B-A264-ACB139BF3909</gtr:id><gtr:title>Identifying children with tuberculosis among household contacts in The Gambia.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/647342215b81b4d4dcd4d8a5b67db65a"><gtr:id>647342215b81b4d4dcd4d8a5b67db65a</gtr:id><gtr:otherNames>Egere U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>58b0a9992e6688.51503252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62DCC719-7302-475E-B0FD-71A9942F5C4A</gtr:id><gtr:title>The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study.</gtr:title><gtr:parentPublicationTitle>Emerging themes in epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/789a421d44fb12ab4f55d9e4e5efddd0"><gtr:id>789a421d44fb12ab4f55d9e4e5efddd0</gtr:id><gtr:otherNames>Bottomley C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-7622</gtr:issn><gtr:outcomeId>56cf4a9f108364.17243007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D84288A-F632-4BB2-B2F4-9DDC16000CB0</gtr:id><gtr:title>Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dfbe18f3e93c5944ceac8518175a916"><gtr:id>4dfbe18f3e93c5944ceac8518175a916</gtr:id><gtr:otherNames>Martellet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cf4a462225e3.86597708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF43DE55-1213-49C1-90A4-EB1279507F78</gtr:id><gtr:title>HIV and tuberculosis in children: biology meets epidemiology.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff0ce7c349f66f838975792025ead9f1"><gtr:id>ff0ce7c349f66f838975792025ead9f1</gtr:id><gtr:otherNames>Seddon JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56cf4a442ca0d9.12249021</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4C8F2DD-0035-460D-A8BC-10BFF1D6978E</gtr:id><gtr:title>Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/369bb73cc7f56116e9875ea77b3da19c"><gtr:id>369bb73cc7f56116e9875ea77b3da19c</gtr:id><gtr:otherNames>Tapia MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cf4a4573c051.20743477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08166B93-B0F4-4562-901C-169A06724B17</gtr:id><gtr:title>Immunological consequences of strain variation within the Mycobacterium tuberculosis complex.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58b0a9996e9f70.00743134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FDB8C3A-1BD0-4A42-885A-F3188322DF9C</gtr:id><gtr:title>The influence of paediatric HIV infection on circulating B cell subsets and CXCR5(+) T helper cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3da9d74f94d2e484bd71b0b6e6e2f9d6"><gtr:id>3da9d74f94d2e484bd71b0b6e6e2f9d6</gtr:id><gtr:otherNames>Bamford A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>56cf4a9a8e46e2.14674233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C73ECA8-D0BE-413A-A757-87B7E64AC536</gtr:id><gtr:title>Comparison of TB-LAMP, GeneXpert MTB/RIF and culture for diagnosis of pulmonary tuberculosis in The Gambia.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c13d5c3426d3d9cf62b9a40f941977f6"><gtr:id>c13d5c3426d3d9cf62b9a40f941977f6</gtr:id><gtr:otherNames>Bojang AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>56cf4a9e0a8c96.38473990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90C5D6E7-1BFB-4992-A16E-78E89A808AB4</gtr:id><gtr:title>Tuberculosis in young refugees.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad775efcab9e8ebd79fe6cedaff47818"><gtr:id>ad775efcab9e8ebd79fe6cedaff47818</gtr:id><gtr:otherNames>Ritz N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56cf4a43e9a382.21122319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77D84E48-911E-4268-849E-409BC2F61FB6</gtr:id><gtr:title>Neonatal admissions, quality of care and outcome: 4 years of inpatient audit data from The Gambia's teaching hospital.</gtr:title><gtr:parentPublicationTitle>Paediatrics and international child health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b991a05bb435b0d9b82486d5bf925bc6"><gtr:id>b991a05bb435b0d9b82486d5bf925bc6</gtr:id><gtr:otherNames>Okomo UA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-9047</gtr:issn><gtr:outcomeId>56cf4a454609d7.42554433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>197B40C3-6FFB-4F69-8B1E-91CC90AB9C1B</gtr:id><gtr:title>Skewing of the CD4(+) T-cell pool toward monofunctional antigen-specific responses in patients with immune reconstitution inflammatory syndrome in The Gambia.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9c8402918ea8e3bd47a06f8f7680221"><gtr:id>e9c8402918ea8e3bd47a06f8f7680221</gtr:id><gtr:otherNames>Wilson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_13512_22_23645847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C315D5B3-B634-41EC-9C87-9AECE4F3BCB1</gtr:id><gtr:title>Short course treatment for MDR TB: jumping the gun?</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c159370750a8c30de0c07f31162d2e5"><gtr:id>4c159370750a8c30de0c07f31162d2e5</gtr:id><gtr:otherNames>Turkova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>5a9eed071e92b6.75413598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7F55516-D2D3-482A-9BDB-74BF0FE55C7E</gtr:id><gtr:title>Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5149d219d7240db05041302902c6636"><gtr:id>b5149d219d7240db05041302902c6636</gtr:id><gtr:otherNames>Lange C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>545bcfec3da585.49325604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A36649E2-2810-40A2-9C9F-52492F79D849</gtr:id><gtr:title>The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2765a26bdd37caa8fbd71943ba6d74a8"><gtr:id>2765a26bdd37caa8fbd71943ba6d74a8</gtr:id><gtr:otherNames>Gehre F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>58b0a99a7398f5.03259478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44F7B1ED-2BEE-474D-930D-1309607CB96F</gtr:id><gtr:title>Preventive chemotherapy for contacts of MDR-TB: is the proof in the pudding?</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5149d219d7240db05041302902c6636"><gtr:id>b5149d219d7240db05041302902c6636</gtr:id><gtr:otherNames>Lange C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>545bcf9a652e73.33593469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C6A0A1D-8D5A-46C4-B13F-FDB6EA58E40E</gtr:id><gtr:title>Short communication: prevalence of antibodies against Coxiella burnetii (Q fever) in children in The Gambia, West Africa.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e32f50185a50d4fb1d6cac7c7f40e42c"><gtr:id>e32f50185a50d4fb1d6cac7c7f40e42c</gtr:id><gtr:otherNames>van der Hoek W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn><gtr:outcomeId>pm_13512_22_23600611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD20AA32-21A2-42FA-94E9-CF99AE14DD84</gtr:id><gtr:title>Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: Study protocol of a randomized efficacy trial.</gtr:title><gtr:parentPublicationTitle>BMC pregnancy and childbirth</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2393</gtr:issn><gtr:outcomeId>56cf4a9ebc6b78.18410532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2E482F5-85BC-4D62-B4CA-1BA31DD28044</gtr:id><gtr:title>Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>56cf4a4458e846.69718725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17430DCD-EE11-46BE-9AFB-F15D2BAB98E0</gtr:id><gtr:title>In reply.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/647342215b81b4d4dcd4d8a5b67db65a"><gtr:id>647342215b81b4d4dcd4d8a5b67db65a</gtr:id><gtr:otherNames>Egere U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>5a9eed084fa062.34650032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BDA4A5C-F669-42E9-808C-604E7A6414AE</gtr:id><gtr:title>Regulatory T Cells and Pro-inflammatory Responses Predominate in Children with Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e215d3d2f61c4984527ff9810e968eb"><gtr:id>2e215d3d2f61c4984527ff9810e968eb</gtr:id><gtr:otherNames>Whittaker E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9eed081af406.08705647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F23582F-38D0-4466-83EE-E1BFB0DD3112</gtr:id><gtr:title>Serogroup W135 meningococcal disease, The Gambia, 2012.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16027f09a1b1e435dac44e980eb7c9a1"><gtr:id>16027f09a1b1e435dac44e980eb7c9a1</gtr:id><gtr:otherNames>Hossain MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>pm_13512_22_23965435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D26F77BF-8C6F-4BE9-BEC9-0C2E7101C5E5</gtr:id><gtr:title>The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff0ce7c349f66f838975792025ead9f1"><gtr:id>ff0ce7c349f66f838975792025ead9f1</gtr:id><gtr:otherNames>Seddon JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58b0a99a9e8f34.22848941</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9312DBC1-02CB-4FE4-81CE-CFD81DD9CBFA</gtr:id><gtr:title>Factors influencing innate immunity and vaccine responses in infancy.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda45a6a26a4e43dac5e1b063bbf789a"><gtr:id>cda45a6a26a4e43dac5e1b063bbf789a</gtr:id><gtr:otherNames>Kampmann B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>56cf4a9b8781a0.71939197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EFDE49E-087B-4574-BC85-C8CBAFB158DE</gtr:id><gtr:title>Salmonella Infections in The Gambia, 2005-2015.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb6e9d0c984ddf71b44ca96330dafa46"><gtr:id>bb6e9d0c984ddf71b44ca96330dafa46</gtr:id><gtr:otherNames>Kwambana-Adams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cf4a45e73669.82362170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57BAD3E5-A113-4C64-82B6-BD5B4CCD7B99</gtr:id><gtr:title>Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_13512_22_23856715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F7CC0BE-BB81-49B4-941A-E67BDF0FE8E4</gtr:id><gtr:title>Management of paediatric tuberculosis in leading UK centres: unveiling consensus and discrepancies.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c159370750a8c30de0c07f31162d2e5"><gtr:id>4c159370750a8c30de0c07f31162d2e5</gtr:id><gtr:otherNames>Turkova A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>545bcf9a8d2488.01897905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95D41218-1A37-4113-8DD5-F0D89812ECF4</gtr:id><gtr:title>Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia.</gtr:title><gtr:parentPublicationTitle>Public health action</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/647342215b81b4d4dcd4d8a5b67db65a"><gtr:id>647342215b81b4d4dcd4d8a5b67db65a</gtr:id><gtr:otherNames>Egere U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2220-8372</gtr:issn><gtr:outcomeId>58b0a999a12bd8.88708945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F0399A1-433B-478B-8558-24D7D445775D</gtr:id><gtr:title>Human breast milk: A review on its composition and bioactivity.</gtr:title><gtr:parentPublicationTitle>Early human development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ca7a078b4d2465cf187b1ce7015d883"><gtr:id>4ca7a078b4d2465cf187b1ce7015d883</gtr:id><gtr:otherNames>Andreas NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-3782</gtr:issn><gtr:outcomeId>56cf4a44c3f601.40458364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E2DD57F-DA01-4D30-92D9-4F1536C31A1B</gtr:id><gtr:title>Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>58b0a99aca7072.13190159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>943DA826-79FC-4A99-A608-E59AA7C1B5A2</gtr:id><gtr:title>Multidrug-resistant tuberculosis in UK children: presentation, management and outcome.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89e58fb4243e402c0edd05290c44155"><gtr:id>d89e58fb4243e402c0edd05290c44155</gtr:id><gtr:otherNames>Williams B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn><gtr:outcomeId>pm_13512_22_23728407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>596B7F86-B8D6-419C-BFB3-E308FB0734C8</gtr:id><gtr:title>Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c84a57e2de07c209dc3eb51a68b9fb94"><gtr:id>c84a57e2de07c209dc3eb51a68b9fb94</gtr:id><gtr:otherNames>Fletcher HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn><gtr:outcomeId>pm_13512_22_23986316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCC6D0AC-EB8C-4FED-A510-7679F950E323</gtr:id><gtr:title>IL-17 Production from T Helper 17, Mucosal-Associated Invariant T, and ?d Cells in Tuberculosis Infection and Disease.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3f7bbbedddc2abc66772e2cf6dc4233"><gtr:id>f3f7bbbedddc2abc66772e2cf6dc4233</gtr:id><gtr:otherNames>Coulter F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5a9eed0568a811.18589901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F70957FE-D105-4880-8260-9BCF1DFAC47F</gtr:id><gtr:title>Immune oxysterols: Role in mycobacterial infection and inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3816ad8792b42d8ca116f2ec9763882f"><gtr:id>3816ad8792b42d8ca116f2ec9763882f</gtr:id><gtr:otherNames>Bah SY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>58b0a99b050887.26182475</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8B2171B-349E-4585-BEC7-BDA794F98DBD</gtr:id><gtr:title>Association of slow recovery of Mycobacterium africanum-infected patients posttreatment with high content of Persister-Like bacilli in pretreatment sputum.</gtr:title><gtr:parentPublicationTitle>International journal of mycobacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2ecf50e86c7e8e51297ab5a17dc502c"><gtr:id>f2ecf50e86c7e8e51297ab5a17dc502c</gtr:id><gtr:otherNames>Tientcheu LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2212-5531</gtr:issn><gtr:outcomeId>58b0a99a095752.85813039</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_MR/K011944/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>